Re: Gilbar et al. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian regional cancer centre. J Oncol Phram Pract, published online January 2018. DOI: 10.1177/1078155217752077 Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion?

Machida Shizuo; Matsubara Shigeki; Fujiwara Hiroyuki; Takei Yuji

首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Re: Gilbar et al. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian regional cancer centre. J Oncol Phram Pract, published online January 2018. DOI: 10.1177/1078155217752077 Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion?

【24h】

Re: Gilbar et al. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian regional cancer centre. J Oncol Phram Pract, published online January 2018. DOI: 10.1177/1078155217752077 Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion?

机译：Re：Gilbar等人。在过去30天的生命的全身抗癌疗法：来自澳大利亚区域癌症中心的回顾性审计。 J Oncol Phram实践，在线发布2018年1月。Doi：10.1177 / 1078155217752077知情同意癌症患者的生活结束化疗：我们应该在多大程度上向患者提供个人意见？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners》 |2019年第1期|共2页
作者
Machida Shizuo; Matsubara Shigeki; Fujiwara Hiroyuki; Takei Yuji;
展开▼
作者单位

Jichi Med Univ Dept Obstet &

Gynecol 3311-1 Yakushiji Shimotsuke Tochigi 3290498 Japan;

Jichi Med Univ Dept Obstet &

Gynecol 3311-1 Yakushiji Shimotsuke Tochigi 3290498 Japan;

Jichi Med Univ Dept Obstet &

Gynecol 3311-1 Yakushiji Shimotsuke Tochigi 3290498 Japan;

Jichi Med Univ Dept Obstet &

Gynecol 3311-1 Yakushiji Shimotsuke Tochigi 3290498 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献

1. Re: Gilbar et al. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian regional cancer centre. J Oncol Phram Pract, published online January 2018. DOI: 10.1177/1078155217752077 Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion? [J] . Machida Shizuo, Matsubara Shigeki, Fujiwara Hiroyuki, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2019,第1期

机译：Re：Gilbar等人。在过去30天的生命的全身抗癌疗法：来自澳大利亚区域癌症中心的回顾性审计。 J Oncol Phram实践，在线发布2018年1月。Doi：10.1177 / 1078155217752077知情同意癌症患者的生活结束化疗：我们应该在多大程度上向患者提供个人意见？
2. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. [J] . Derya Hopanci Bicakli, Umut Varol, Mustafa Degirmenci, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2015,第4期

机译：回复编辑，Re：Bicakli等。辅助化疗可能会增加乳腺癌患者发生代谢综合征的风险。 J Oncol Pharm Pract，在线发表于2014年9月。DOI：10.1177 / 1078155214551315。
3. Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. [J] . Mehmet Agilli, Fevzi Nuri Aydin Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2015,第4期

机译：回复：Bicakli等。辅助化疗可能会增加乳腺癌患者发生代谢综合征的风险。 J Oncol Pharm Pract，在线发表于2014年9月。DOI：10.1177 / 1078155214551315。
4. Anticancer therapy within the last 30 days of life: results of an audit and re-audit cycle from an Australian regional cancer centre [O] . Mike Nguyen, Sean Ng Ying Kin, Evonne Shum, 2020

机译：生命最后30天内的抗癌治疗：来自澳大利亚地区癌症中心的审核和重新审核周期的结果
5. Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion? [O] . Shizuo Machida, Shigeki Matsubara, Hiroyuki Fujiwara, 2018

机译：知情同意癌症患者的生活终末化疗：我们应该在多大程度上向患者提供个人意见？

著录项

相似文献

相关主题

期刊订阅